Press Releases

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ef5944/protein_kinase_the) has announced the addition of the "Protein Kinase Therapeutics in Oncology - Where to Commercialize?" report to their offering.

This report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. The report extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target profiles, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

    --  Providing you with competitive input to the R&D organization to guide
        development of early product ideas and ensure efforts are aligned with
        business objectives
    --  Assisting you to make informed decisions in selecting cancer indications
        that are known to be appropriate for your drug's properties
    --  Analyzing, correlating and integrating valuable data sources in order to
        provide accurate data for valuation of pipeline, in-licensing and new
        business opportunities
    --  Providing you with commercial analytic support for due diligence on
        in-licensing and acquisition opportunities
    --  Integrating knowledge for you to consider the therapeutic target for the
        highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

Key Topics Covered:

    --  1 Executive Summary
    --  2 About Cancer Highlights
    --  3 Methodologies
    --  4 Overview
    --  5 Introduction
    --  6 Consider the Therapeutic Target for the Highest Therapeutic Outcome
        and Return on Investment
    --  7 The Rise of New Products: How Mature, Unique and Clinically Validated
        are the Drug Target Profiles Identified in the Cancer Protein Kinase
        Therapeutic Pipeline?
    --  8 Compound Strategies at Work: Competitive Benchmarking of Protein
        Kinase Drugs in Oncology by Compound Type
    --  9 Selecting Cancer Indications for Protein Kinase Therapeutics
    --  10 Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer
        Therapeutic Pipeline by Investigator
    --  11 Disclaimer
    --  12 Drug Index
    --  13 Company Index
    --  4.1 List of Figures
    --  4.1 List of Figures

Companies Mentioned:

    --  AB Science
    --  Abbott
    --  Bayer
    --  Cancer Research Technology
    --  Celgene
    --  Exelixis
    --  Galapagos
    --  Insmed
    --  Johnson & Johnson
    --  Kirin Pharma
    --  KuDOS
    --  Kyowa Hakko Kirin
    --  Novogen
    --  Oncalis
    --  Pfizer
    --  Provid
    --  QLT
    --  Quantum Pharmaceuticals
    --  Ras Therapeutics
    --  Sareum
    --  SBIO
    --  Scancell
    --  Schering-Plough
    --  ToolGen
    --  TopoTarget
    --  UCB
    --  VasGene Therapeutics
    --  ViroMed
    --  Wyeth
    --  Xencor

For more information visit http://www.researchandmarkets.com/research/ef5944/protein_kinase_the

    Source: Research and Markets

HENDERSON, Nev., Nov. 11 /PRNewswire-FirstCall/ -- Healthy Fast Food, Inc. (OTC Bulletin Board: HFFI), the owner and franchisor of U-SWIRL® Frozen Yogurt stores, today announced that it has initiated construction on its sixth Company-owned U-SWIRL self-serve frozen yogurt store serving the Las Vegas valley.

Located at 9360 W. Flamingo Road just east of Fort Apache Road, construction on the new U-SWIRL store is expected to be completed in February 2010. The 2578 square foot "Super Swirl" store will feature 20 flavors of self-serve frozen yogurt and allow guests to choose from over 60 delicious toppings. After creating their own individual frozen yogurt concoctions - paying by the ounce, not by the cup size - guests will be able to relax and enjoy their treats in comfortable indoor and outdoor seating areas.

According to Terry Cartwright, Vice President of Development, "We are pleased to continue our expansion of U-SWIRL Frozen Yogurt stores in the Las Vegas market, further strengthening our local presence and enhancing consumer awareness of our exciting self-serve concept and the U-SWIRL brand."

With the opening of this new location, it will bring the total number of Company-owned and franchised U-SWIRL's in operation to eight - seven in the Vegas valley and one in Reno, Nevada. Healthy Fast Food recently announced that it also just signed a franchise area development agreement in Phoenix, Arizona to open a minimum of 18 new U-SWIRL Frozen Yogurt stores in that expansion market.

ABOUT HEALTHY FAST FOOD, INC.

Headquartered in Henderson, Nevada, Healthy Fast Food, Inc. is on a mission to deliver consumers a smarter alternative to America's favorite meals and snacks. In October 2008, the Company acquired the worldwide rights to U-SWIRL® Frozen Yogurt and has commenced executing an aggressive strategy to build the brand into a globally recognized chain of highly experiential frozen yogurt stores, led by its wholly-owned subsidiary, U-SWIRL International, Inc.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Healthy Fast Food, Inc.'s ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Healthy Fast Food's periodic filings with the Securities and Exchange Commission, including without limitation, the Company's Annual Report for the year ended December 31, 2008. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Healthy Fast Food undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

    FOR MORE INFORMATION, PLEASE CONTACT
    Elite Financial Communications Group, LLC
    Dodi Handy, President and CEO (Twitter: @dodihandy) or
    Kathy Addison, Director of Elite Media Group (Twitter: @kathyaddison)
    407-585-1080 or via email at HFFI@efcg.net

SOURCE Healthy Fast Food, Inc.

NEW YORK--(BUSINESS WIRE)-- Fitch Ratings has amended its 'Global Criteria for Cash Flow Analysis in CDOs' to include all CDO types. The report, which was published on Nov. 9, 2009, replaces a report originally published on April 30, 2008. The original 2008 report stated that it did not cover Fitch's approach to rating collateralised debt obligations (CDOs) of structured finance securities, trust preferred securities or commercial real estate loan CDOs. The amended report includes a new paragraph that describes that these criteria do indeed cover these additional asset classes. The core criteria have not changed.

To reflect this amendment, the report title has been updated to expand the coverage of these criteria to all CDOs, from just corporate CDOs. Also, the list of related research has been updated to include those titles published since the date of the original report.

The amended report is available at 'www.fitchratings.com' under the following headers:

Structured Finance >> Structured Credit >> Criteria Reports

Additional information is available at 'www.fitchratings.com'.

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE.

    Source: Fitch Ratings

Near 9% Unemployment Leaves More Idaho Families Struggling with High Health Care Costs - Highlights Need for Reform

BOISE, Idaho, Nov. 11 /PRNewswire-USNewswire/ -- As Idaho's jobless rate approaches 9%, so do the health care worries for the over 67,300 unemployed Idahoans finding themselves without employer benefits. While many have exhausted both state and federal benefits, AARP is calling on Idaho's Congressional delegation to set politics aside and support health care reform measures delivering needed relief to state residents buckling under soaring costs.

"When people lose their jobs they lose their health care benefits - leaving Idahoans struggling to afford even the most basic health care they need for themselves and their families," said Jim Wordelman, State Director for AARP in Idaho. "While Washington debates health care reform, the harsh reality of high health care costs is landing in the middle of kitchen tables across the state forcing many Idaho residents to go without."

For over 221,000 uninsured Idahoans (88% who have jobs), the Affordable Health Care for America Act (H.R. 3962), offers immediate assistance by helping them purchase health care insurance. The AARP-backed legislation recently passed the U.S. House of Representatives and has now been sent to the Senate. Neither Congressman Walt Minnick nor Congressman Mike Simpson supported the measure in the House.

"Now that real health care reform is headed to the Senate, AARP is calling on Senators Crapo and Risch to focus on what's best for Idaho by supporting legislation that helps people get the coverage they need," added Wordelman. "This debate is far from over - Representatives Minnick and Simpson will have another chance to say 'yes' to meaningful health care reform for all Idahoans."

In Idaho, nearly 400,000 residents spend more than 10% of their pre-tax household income on health care costs, while roughly 100,000 spend upwards of a quarter of their income.

For hundreds of thousands of Idahoans who can barely afford skyrocketing health care costs, the legislation strictly limits how much more insurance companies can charge based on age, and stops insurers from denying coverage based on a person's health history or gender. The legislation also closes the dangerous Medicare prescription drug coverage gap known as the "doughnut hole" and allows the program to negotiate lower drug prices. It adds cost-free preventive services like cancer screenings and cracks down on waste and fraud to protect and strengthen traditional Medicare benefits.

AARP has nearly 185,000 members in Idaho.

SOURCE AARP Idaho

MCKINNEY, Texas--(BUSINESS WIRE)-- Encore Wire Corporation (NASDAQ Global Select: WIRE) announced today that the Company's Chief Financial Officer, Mr. Frank J Bilban, will be presenting at the Southwest IDEAS Investor Conference on Thursday, November 12, 2009 at 10:45 a.m. CST.

Daniel L. Jones, President and Chief Executive Officer of Encore Wire Corporation, said, "We are pleased to be presenting at the Southwest IDEAS Investor Conference at the Hilton Anatole Hotel in Dallas, Texas. The conference draws institutional investors from across the country. In addition, the presentation will be available via webcast for those who are unable to attend in person. The webcast link is www.wsw.com/webcast/threepa/wire."

Encore Wire Corporation manufactures a broad range of copper electrical wire for interior wiring in homes, apartments, manufactured housing and commercial and industrial buildings.

The matters discussed in this news release, other than the historical financial information, including statements about the copper pricing environment, profitability and shareholder value, may include forward-looking statements that involve risks and uncertainties, including payment of future dividends, future purchases of stock, fluctuations in the price of copper and other raw materials, the impact of competitive pricing and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission. Actual results may vary materially from those anticipated.

    Source: Encore Wire Corporation